Li Zhiguo, Li Ying, Li Xiaoke, Zhang Ludan, Zhao Nanqi, Du Hongbo, Zhou Bo, Ye Yong'an
Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM) Beijing University of Chinese Medicine Institute of Liver Diseases Centre for Evidence-Based Chinese Medicine, BUCM, Beijing, China.
Medicine (Baltimore). 2018 Aug;97(34):e11950. doi: 10.1097/MD.0000000000011950.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Chronic hepatitis B (HBV) and C virus (HCV) infection causes liver cancer. This protocol is to provide the methods used to assess the relationship between statins and HCC risk in hepatitis B or C patients.
We will search comprehensively the PubMed (medline), Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure, Wanfang Database from their inception to November 2017. We will include studies that evaluated and clearly defined exposure to statins, reported the HCC incidence in hepatitis B/C patients or HBV/HCV-related cirrhosis patients, provided effective comparison groups, and reported risk estimates, such as hazard ratios, relative risks, or odds ratios with corresponding 95% confidence intervals or sufficient data for their estimation. We will use Stata (version 15.0) to compute the data synthesis carefully when a meta-analysis is allowed.
This study will provide a high-quality synthesis of current evidence of statins on HCC risk in hepatitis B or C patients.
The conclusion of our systematic review will provide evidence to judge whether statin is an effective intervention for hepatitis B or C patients.
肝细胞癌（HCC）是全球癌症相关死亡的主要原因。慢性乙型肝炎（HBV）和丙型肝炎病毒（HCV）感染会导致肝癌。本方案旨在提供用于评估他汀类药物与乙肝或丙肝患者肝癌风险之间关系的方法。
我们将全面检索PubMed（医学索引）、Embase、科学引文索引、考克兰图书馆以及中国知网、万方数据库，检索时间从各数据库建库起至2017年11月。我们将纳入评估并明确界定他汀类药物暴露情况、报告乙肝/丙肝患者或HBV/HCV相关肝硬化患者肝癌发病率、提供有效对照组并报告风险估计值（如风险比、相对风险或比值比以及相应的95%置信区间）或有足够数据用于估计这些值的研究。当允许进行荟萃分析时，我们将使用Stata（版本15.0）仔细计算数据合成。
本研究将高质量地综合当前关于他汀类药物对乙肝或丙肝患者肝癌风险影响的证据。
我们系统评价的结论将为判断他汀类药物是否为乙肝或丙肝患者的有效干预措施提供证据。
